Abiomed (NASDAQ: ABMD) reported Q3 EPS of $0.23, $0.08 better than the analyst estimate of $0.15. Revenue for the quarter came in at $85.8 million versus the consensus estimate of $80.04 million.

For earnings history and earnings-related data on Abiomed (ABMD) click here.